Screener
Kymera Therapeutics KYMR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Deferred revenue | — | 22,925 |
| Operating lease liabilities | 12,119 | 11,941 |
| Finance lease liabilities | 1,577 | 1,815 |
| Other current liabilities | 236 | 242 |
| Total current liabilities | $71,326 | $83,212 |
| Non-current liabilities | ||
| Deferred revenue, net of current portion | — | 11,440 |
| Operating lease liabilities, net of current portion | 64,022 | 67,034 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's accrued expenses?
- Kymera Therapeutics (KYMR) reported accrued expenses of $236K in Q2 2026.
- How has Kymera Therapeutics's accrued expenses changed year-over-year?
- Kymera Therapeutics's accrued expenses increased by 101.7% year-over-year, from $117K to $236K.
- What is the long-term trend for Kymera Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Kymera Therapeutics's accrued expenses has grown at a 18.0% compound annual growth rate (CAGR), from $106K to $242K.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Kymera Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude